Last week, the FDA announced that it had officially approved Spravato, a brand-name nasal spray containing esketamine, a chemical cousin of ketamine, to treat depression. The drug was hailed by many as a game-changer, as it’s proven to be an effective therapy for people with treatment-resistance depression (TRD), or approximately …
Read More »Is Esketamine the Game-Changer for Depression We Want?
